New Delhi: Miltenyi Biotec, a biomedical solutions company, has signed a Letter of Intent with the Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology (DBT) under the Union Ministry of Science and Technology.
In a statement, Miltenyi Biotec elaborated on the personalized and targeted approaches that cell and gene therapy provides for patient treatment. The therapy is less burdensome on other cell types in the patient’s body than standard of care chemotherapy. However, cell and gene therapies still require further improvement in scalability and affordability.
The biomedical company stated that the two organizations intend to address the increasing demand for innovative treatments in the battle against cancer by developing innovative cell and gene therapies, with a specific emphasis on cancer and sickle cell disease, through the partnership.
Discussion about this post